Targets › BRDT
4 programs from 4 companies in 11 trials: 7 Phase 1, 3 Phase 3, 1 Phase 2; Oncology, Other, Infectious disease; next expected readout Nov 2026.
Testis-specific chromatin protein that specifically binds histone H4 acetylated at 'Lys-5' and 'Lys-8' (H4K5ac and H4K8ac, respectively) and plays a key role in spermatogenesis. Required in late pachytene spermatocytes: plays a role in meiotic and post-meiotic cells by binding to acetylated histones at the promoter of specific meiotic and post-meiotic genes, facilitating their activation at the appropriate time. (UniProt, Q58F21)
Open in Phaseline: the race on BRDT, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Novartis | Pelabresib Bromodomain and extra-terminal motif (BET) inhibitor | BRD2, BRD4, BRDT, BRD3 | Phase 3 | Hematologic Malignancy; Myelofibrosis; Primary Myelofibrosis (PMF); Healthy Participants … | Nov 2026 |
| Resverlogix | Apabetalone (RVX000222) Bromodomain and extra-terminal motif (BET) inhibitor | BRD2, BRD4, BRDT, BRD3 | Phase 2 | Post-Acute COVID-19 Syndrome | – |
| Chia Tai Tianqing Pharmaceutical Group | TQB3617 Capsules Bromodomain and Extra-Terminal (BET) inhibitor | BRD2, BRD3, BRD4, BRDT | Phase 1 | Myelofibrosis | Dec 2026 |
| Bristol-Myers Squibb | Ezobresib (BMS-986158) Bromodomain and extra-terminal motif (BET) inhibitor | BRD2, BRD4, BRDT, BRD3 | Phase 1 | Multiple Myeloma; Myelofibrosis | Aug 2028 |
Myelofibrosis (3) Primary Myelofibrosis (PMF) (2) Hematologic Malignancy (1) Healthy Participants (1) Advanced Malignancies (1) Advanced Malignancies and Hepatic Impairment (1) Multiple Myeloma (1) Post-Acute COVID-19 Syndrome (1)
small molecule (4)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.